How would gathering preclinical data and improving research infrastructure facilitate clearer definitions of “population vulnerability” and “risk acceptability”?
AMA J Ethics. 2020;22(1):E43-49. doi:
10.1001/amajethics.2020.43.
Aminu Yakubu, Nchangwi Syntia Munung, and Jantina De Vries, PhD
African cancer research is embedded in underresourced health care infrastructures, illuminating ethical questions about benefit sharing and governance.
AMA J Ethics. 2020;22(2):E156-163. doi:
10.1001/amajethics.2020.156.
As larger organizations become more influential in the health care sector, the Code can help physicians navigate those organizations’ influence on their practices.
AMA J Ethics. 2020;22(3):E217-220. doi:
10.1001/amajethics.2020.217.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Corporatization in health care has complicated clinicians’ and organizations’ efforts to balance interests of individual patients against an organization’s bottom line.
AMA J Ethics. 2020;22(3):E187-192. doi:
10.1001/amajethics.2020.187.
Jennifer D. Byrne, LCSW, CADC, Katie S. Clancy, MSW, and Isabell Ciszewski, LCSW
Social work perspectives on whether prescribers should authorize opioid refills emphasize the importance of multidisciplinary approaches to patient self-determination.
AMA J Ethics. 2020;22(8):E658-663. doi:
10.1001/amajethics.2020.658.